Exhibit 10.7.4

FOURTH AMENDMENT TO

GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT

THIS FOURTH AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this
“Fourth Amendment”) is entered into as of November 24, 2015 and effective as of
November 1, 2015 (the “Fourth Amendment Effective Date”) by and between Abbott
Laboratories, a corporation of the state of Illinois, having its principal place
of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”)
and BG Medicine, Inc., a corporation of the state of Delaware, having its
principal place of business at 303 Wyman, Suite 300, Waltham, Massachusetts
02451 (“BGM”).

RECITALS

A. Abbott and BGM are parties to that certain Galectin-3 License and
Distribution Agreement, dated as of November 11, 2009, as amended, (the
“Agreement”), pursuant to which BGM granted Abbott a license under BGM’s Patent
Rights to commercialize Products in the Territory.

B. The Parties now desire to amend the Agreement to amend the Product Fee paid
by Abbott, among other things.

NOW, THEREFORE, in consideration of the mutual covenants and agreement contained
herein, and upon the terms and subject to the conditions set forth below, Abbott
and BGM hereby agree as follows:

AMENDMENT

 

1. Except as modified by this Amendment, capitalized terms used and not
otherwise defined herein shall have the meanings given to them in the Agreement.

 

2. Section 1.2, “AUP”, is hereby deleted in its entirety and replaced with the
following:

1.2 “AUP” shall mean those references made in this Agreement comprised of both
AUP-H and AUP-R collectively, or individually, as appropriate and all such
references within a Section, Subsection, Table or Exhibit to this Agreement
unless otherwise indicated.

1.2(h) “AUP-H” is the total sales of Tests to unaffiliated Hospital Customers
(as hereinafter defined), calculated in Dollars on a Calendar Quarter basis, in
an arm’s length transaction, divided by the number of Tests sold to unaffiliated
Hospital Customers in an arm’s length transaction by Abbott or its Affiliates in
such Calendar Quarter.

1.2(r) “AUP-R” is the total sales of Tests to unaffiliated Reference Lab
Customers (as hereinafter defined), calculated in Dollars on a Calendar Quarter
basis, in an arm’s length

 

Page 1

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have
been filed separately with the Securities and Exchange Commission pursuant to
the Registrant’s application requesting confidential treatment pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

--------------------------------------------------------------------------------

transaction, divided by the number of Tests sold to unaffiliated Reference Lab
Customers in an arm’s length transaction by Abbott or its Affiliates in such
Calendar Quarter.

 

3. Section 1.9 is hereby deleted in its entirety and replaced with the
following:

1.9 “Hospital Customer” means any Third Party to whom Tests are sold and billed
by Abbott for such Tests, where such billed Third Party is a hospital,
university, public health facility, clinic or physician office.

 

4. A new Section 1.13A shall be added to the Agreement as follows:

1.13A “Reference Lab Customer” means any Third Party to whom Tests are sold
other than a Hospital Customer. For the avoidance of doubt, a laboratory housed
in a hospital, university, public health facility or physician office that is
owned, managed or operated by a Third Party that has been retained by such
hospital, university, public health facility or physician office to provide
clinical laboratory services through, as an example, test outsourcing,
management outsourcing, or other professional and/or consulting services, is
considered a Reference Lab Customer.

 

5. Section 3.1 is hereby deleted in its entirety and replaced with the
following:

 

  3.1 Product Fee.

 

  (a) [***], as consideration for the rights and licenses granted by BGM to
Abbott and its Affiliates and BGM’s agreement to the other terms and conditions
set forth in this Agreement, Abbott shall pay to BGM a fee as set forth in this
Section 3.1, and as shown below in Table 3.1 (the “Product Fee”) for Tests sold
to Third Parties in the Territory.

 

  (b) Unless otherwise agreed to by the Parties in writing, or as provided in
Section 3.1(f) below, the Product Fee applicable for each Test sold to a
Hospital Customer [***] the following tiers shall apply to the Product Fee owed
in such Calendar Quarter for sales of Tests to Hospital Customers:

 

  (i) Cumulative Test sales by Abbott or its Affiliates to unaffiliated Third
Parties from [***];

 

  (ii) Cumulative Test sales by Abbott or its Affiliates to unaffiliated Third
Parties from [***]; and

 

  (iii) Cumulative Test sales by Abbott or its Affiliates to unaffiliated Third
Parties from [***].

 

  (c) [***] Abbott shall pay the Product Fee stipulated in Section 3.1(b),
subject to the provisions of Section 3.13 on completion of the renegotiation.

 

Page 2

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have
been filed separately with the Securities and Exchange Commission pursuant to
the Registrant’s application requesting confidential treatment pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

--------------------------------------------------------------------------------

  (d) [***] Provided, however, that in no event shall [***] that was being paid
by Abbott for [***] immediately prior to the [***].

 

Table 3.1

PRODUCT FEE APPLICABLE TO SALES OF TESTS [***]

AUP-H   

Cumulative Test sales volume from

[***]

  

TIER 1
[***]

(baseline Product Fee)

   TIER 2
[***]
[***]    TIER 3
[***]
[***]   

Product Fee

   [***]    Product Fee    [***]    Product Fee    [***] [***]    [***]    [***]
   [***]    [***]    [***]    [***] [***]    [***]    [***]    [***]    [***]   
[***]    [***] [***]    [***]    [***]    [***]    [***]    [***]    [***] [***]
   [***]    [***]    [***]    [***]    [***]    [***] [***]    [***]    [***]   
[***]    [***]    [***]    [***] [***]    [***]    [***]    [***]    [***]   
[***]    [***] [***]    [***]    [***]    [***]    [***]    [***]    [***]

 

  (e) [***] unless otherwise agreed to by the Parties in writing, or as provided
in Section 3.1(f) below, the Product Fee applicable for each Test sold to a
Reference Lab Customer [***] shall be [***].

 

  (f) Subject to the other terms and conditions of this Agreement, [***] the
Parties shall [***].

 

6. A new Section 3.2(c) shall be added to the Agreement as follows:

3.2(c) In consideration for the reduction of the Product Fee applicable for each
Test sold to a Reference Lab Customer as part of this Fourth Amendment, and as a
buy-down of future Product Fees owed for such sales, Abbott shall pay BGM the
following payments:

 

  (i) Five Hundred Thousand Dollars ($500,000) within thirty (30) days of the
Fourth Amendment’s Effective Date. This payment set forth in this
Section 3.2(c)(i) shall be non-refundable and shall not be applied against
future Product Fees owed by Abbott to BGM under this Agreement; and

 

  (ii) An amount not to exceed Five Hundred Thousand Dollars ($500,000.00)
payable by June 30, 2016, if the following [***] have been met: [***]. The total
amount payable by Abbott, if any, shall be calculated as follows:

 

Page 3

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have
been filed separately with the Securities and Exchange Commission pursuant to
the Registrant’s application requesting confidential treatment pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

--------------------------------------------------------------------------------

TABLE 3.2(c)(ii)

PAYMENT CALCULATION

[***]    [***] [***]    [***] [***]    [***] [***]    [***] [***]    [***] [***]
   [***] [***]    [***]

Once paid, this payment set forth in this Section 3.2(c)(ii) shall be
non-refundable and shall not be applied against future Product Fees owed by
Abbott to BGM under this Agreement.

 

7. Except as expressly amended by this Fourth Amendment, all of the terms and
conditions of the Agreement remain in full force and effect.

 

8. This Fourth Amendment may be executed in two (2) original counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

IN WITNESS WHEREOF, the Parties have executed this Fourth Amendment as of the
date first above written.

 

ABBOTT LABORATORIES     BG MEDICINE, INC. By:   /s/ Brian J. Blaser     By:  
/s/ Paul R. Sohmer

Name:

Title:

 

Brian J. Blaser

Executive Vice President

President, Diagnostics

   

Name:

Title:

 

Paul R. Sohmer

President & CEO

 

Page 4

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have
been filed separately with the Securities and Exchange Commission pursuant to
the Registrant’s application requesting confidential treatment pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.